Abstract
Background
Emerging evidence suggests that metformin decreases the risk of developing colorectal cancer in patients with diabetes, but only few studies have examined potential survival benefits after surgery for colorectal cancer (CRC). The purpose of the study was to examine the association between diabetes and overall survival after resection for CRC. Furthermore, the association between antidiabetic medication and overall survival was examined.
Methods
Patients diagnosed with CRC between January 1, 2003 and December 31, 2012 were identified through the Danish Colorectal Cancer Group’s National Clinical Database (DCCG). The Danish National Patient Register (NPR) records all hospital contacts in Denmark, and the diagnosis of diabetes was identified by combining NPR data with use of antidiabetic drugs identified through the Danish National Prescription Registry and DCCG. The Kaplan–Meier estimator and the Cox regression model adjusted for important clinical risk factors were used.
Results
A total of 30,493 patients were included in the study, of which 3391 were diagnosed with diabetes and 1962 were treated with metformin. The adjusted HR of all-cause mortality for the diabetes group was 1.12 (1.06–1.18, p < 0.0001) compared with the nondiabetes group. The adjusted HR was 0.85 (0.73–0.93, p = 0.03) for the metformin-treated group compared with the insulin-treated group.
Conclusions
A 12 % increase in all-cause mortality among patients with CRC and diabetes was found. Treatment with metformin was associated with a 15 % decreased all-cause mortality compared with patients with insulin-treated diabetes.
Similar content being viewed by others
References
Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2013;22(12):2258–68.
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–87.
Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6):57.
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JPA. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:7607.
Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26:863–76.
Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci. 2010;55(7):1839–51.
Danish Colorectal Cancer Database [yearly Report 2013] http://www.dccg.dk/03_Publikation/2013.pdf 2013.
Barone BB, Yeh H-C, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.
Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433–40.
Gross CP, Guo Z, McAvay GJ, Allore HG, Young M, Tinetti ME. Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc. 2006;54:1898–04.
Mei Z-B, Zhang Z-J, Liu C-Y, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One. 2014;9(3):e91818.
Sehdev A, Shih YCT, Vekhter B, Bissonnette MB, Olopade OI, Polite BN. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a U.S. population. Cancer. 2014;121:1–8.
Barco S Del, Vazquez-martin A, Cufí S, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011;2(12):896–917.
Zhang Z-J, Zheng Z-J, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34(10):2323–8.
Lee JH, Kim T Il, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131(3):752–9.
Garrett CR, Hassabo HM, Bhadkamkar NA, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012;106(8):1374–8.
Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish civil registration system: a cohort of eight million persons. Dan Med Bull. 2006;53:441–9.
Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39:30–3.
Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011;39:38-41.
Vandenbroucke JP, vonElm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–94.
Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005;2:48–53.
Landman GWD, Kleefstra N, Van Hateren KJJ, Groenier KH, Gans ROB, Bilo HJG. Metformin associated with lower cancer mortality in type 2 diabetes: zodiac-16. Diabetes Care. 2010;33:322–6.
Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3(11):1451–61.
Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–5.
Acknowledgment
The work was supported by a Grant from Arvid Nilssons Foundation. The authors thank Dr. Sara Kehlet Watt for editing services.
Author contribution
The foundation had no influence on the design or conduct of the study, collection, management, analysis or interpretation of the data or preparation, review or approval of the manuscript.
Disclosure
There are no personal conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fransgaard, T., Thygesen, L.C. & Gögenur, I. Metformin Increases Overall Survival in Patients with Diabetes Undergoing Surgery for Colorectal Cancer. Ann Surg Oncol 23, 1569–1575 (2016). https://doi.org/10.1245/s10434-015-5028-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-015-5028-8